文章预览
SCI 27 August 2024 Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial （J Clin Oncol;IF:42.1） Yagisawa M, Taniguchi H, Satoh T, Kadowaki S, Sunakawa Y, Nishina T, Komatsu Y, Esaki T, Sakai D, Doi A et al: Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial. J Clin Oncol 2024:Jco2302626. Correspondence to：Hiroya Taniguchi, MD, PhD; e-mail: hiroya.taniguchi@aichi-cc.jp. PURPOSE 目的 HERALD/EPOC1806 was conducted as a multicenter phase II trial assessing trastuzumab deruxtecan (T-DXd) therapy for patients with human epidermal growth factor receptor 2 (HER2)–amplified progressive stage solid tumors detected by cell-free DNA (cfDNA) testing. HERALD/EPOC1806是一项多中心2期试验，
………………………………
